Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.

Breast cancer research : BCR - 13 Jan 2015

Blanchard Zannel, Paul Bibbin T, Craft Barbara, ElShamy Wael M

Abstract excerpt

INTRODUCTION: Intrinsic or acquired chemoresistance is a major problem in oncology. Although highly responsive to chemotherapies such as paclitaxel, most triple negative breast cancer (TNBC) patients develop chemoresistance. Here we investigate the role of BRCA1-IRIS as a novel treatment target f...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Epithelial-Mesenchymal Transition
Share to Forkhead Box Protein O3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitor of Apoptosis Proteins

Share to Paclitaxel

Share to Proteolysis

Share to Survivin

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 25583261
DOI: 10.1186/s13058-014-0512-9
PMCID: PMC4322455

Genes

BRCA1
EGF
EGFR
NRG1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25583261-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.PMID 25583261Read ↗

BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.Semantic proximity Read ↗

Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.Semantic proximity Read ↗

Integrin β4 promotes DNA damage-related drug resistance in triple-negative breast cancer via TNFAIP2/IQGAP1/RAC1Semantic proximity Read ↗

Integrin β4 promotes DNA damage-related drug resistance in triple-negative breast cancer via TNFAIP2/IQGAP1/RAC1Semantic proximity Read ↗

FOXA1 is a determinant of drug resistance in breast cancer cellsSemantic proximity Read ↗

p53, BRCA1 and breast Cancer chemoresistance.Semantic proximity Read ↗

The role of Six1 signaling in paclitaxel-dependent apoptosis in MCF-7 cell lineSemantic proximity Read ↗

BOP1 confers chemoresistance of triple‐negative breast cancer by promoting CBP‐mediated β‐catenin acetylationSemantic proximity Read ↗

eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancerSemantic proximity Read ↗

BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.Semantic proximity Read ↗

Targeting the Id1-Kif11-Aurka axis in triple negative breast cancer using combination therapySemantic proximity Read ↗

BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.